<SEC-DOCUMENT>0001213900-24-078663.txt : 20240913
<SEC-HEADER>0001213900-24-078663.hdr.sgml : 20240913
<ACCEPTANCE-DATETIME>20240913172524
ACCESSION NUMBER:		0001213900-24-078663
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20240913
FILED AS OF DATE:		20240913
DATE AS OF CHANGE:		20240913

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Moolec Science SA
		CENTRAL INDEX KEY:			0001937737
		STANDARD INDUSTRIAL CLASSIFICATION:	BLANK CHECKS [6770]
		ORGANIZATION NAME:           	04 Manufacturing
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			N4
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41586
		FILM NUMBER:		241298708

	BUSINESS ADDRESS:	
		STREET 1:		17, BOULEVARD F.W. RAIFFEISAN
		CITY:			LUXEMBOURG
		STATE:			N4
		ZIP:			L-2411
		BUSINESS PHONE:		352 26 49 65 65

	MAIL ADDRESS:	
		STREET 1:		17, BOULEVARD F.W. RAIFFEISAN
		CITY:			LUXEMBOURG
		STATE:			N4
		ZIP:			L-2411
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0214594-6k_moolec.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>UNITED STATES</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Washington, D.C. 20549</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Form&nbsp;6-K</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Report of Foreign Private Issuer</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Pursuant to Rules&nbsp;13a-16 or 15d-16 under</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>the Securities Exchange Act of 1934</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>For the month of September 2024</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Commission File Number: 001-41586</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>MOOLEC SCIENCE SA </B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">(Exact name of Registrant as Specified in Its Charter)</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>17, Boulevard F. W. Raiffeisen</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>L-2411 Luxembourg,</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Grand Duchy of Luxembourg</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">(Address of principal executive offices)</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover Form&nbsp;20-F or Form&nbsp;40-F.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: -1.5in; margin: 0pt 0 0pt 1.5in">Form&nbsp;20-F&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Form&nbsp;40-F&nbsp;&nbsp;&#9744;</P>

<P STYLE="margin: 0pt 0 0pt 1.5in; font-size: 10pt; text-align: center; text-indent: -1.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0 0pt 1.5in; font-size: 10pt; text-align: center; text-indent: -1.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0pt 0 0pt 1.5in; font-size: 10pt; text-align: center; text-indent: -1.5in"></P>




<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Exhibit List</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Exhibit No.&nbsp;</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 89%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Description&nbsp;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="ea021459401ex99-1_moolec.htm"><FONT STYLE="font-size: 10pt">Press Release of Moolec Science SA dated September 13, 2024.</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>




<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>SIGNATURES</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MOOLEC SCIENCE SA</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: September 13, 2024</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Gast&oacute;n
    Paladini</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp; </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gast&oacute;n Paladini</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">2</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea021459401ex99-1_moolec.htm
<DESCRIPTION>PRESS RELEASE OF MOOLEC SCIENCE SA DATED SEPTEMBER 13, 2024
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Moolec Received Nasdaq Bid Price Letter</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Luxembourg. September <FONT STYLE="background-color: white">13</FONT>,
2024.</B> Moolec Science SA (NASDAQ: MLEC; &ldquo;The Company&rdquo;, &ldquo;Moolec&rdquo;), a science-based food ingredient company,
announced today that it received a letter (the &ldquo;Nasdaq Bid Price Letter&rdquo;) from Nasdaq notifying the Company that, for the
last 30 consecutive business days, the closing bid price for the Company&rsquo;s ordinary shares has been below the minimum $1.00 per
share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Nasdaq Bid Price Letter has no immediate effect
on the listing of the Company&rsquo;s common stock, and its common stock will continue to trade on The Nasdaq Capital Market under the
symbol &ldquo;MLEC&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under Rule 5810(c)(3)(A), the Company will be
provided a compliance period of 180 calendar days, until March 10, 2025<B>,</B> to regain compliance. If at any time during this 180-day
period the closing bid price of the Company&rsquo;s securities is at least $1.00 for a minimum of ten consecutive business days, the Company&rsquo;s
compliance with Rule 5550(a)(2) will be regained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event the Company does not regain compliance
in the first compliance period, it may be eligible to apply for an additional 180 calendar days to regain compliance. To qualify, the
Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing
standards for The Nasdaq Capital Market, with the exception of the bid price requirement. The Company will also need to provide written
notice of its intention to cure the deficiency during the second compliance period. However, if it appears to the NASDAQ staff that the
Company will neither be able nor otherwise eligible to cure the deficiency, it may be subject to delisting by NASDAQ. The Company is committed
to regaining compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company intends to actively monitor the closing
bid price for its ordinary shares and will consider available options to resolve the deficiency and regain compliance with Rule 5550(a)(2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Moolec Science SA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Moolec is a science-based ingredient company leader
in the use of Molecular Farming technology for the food and dietary supplementation markets. The Company&rsquo;s mission is to create
unique food ingredients by engineering plants with animal protein genes. Its purpose is to redefine the way the world produces animal
proteins for the good of the planet. Moolec&rsquo;s technological approach aims to have the cost structure of plant-based solutions with
the nutrition and functionality of animal-based ones. The Company&rsquo;s technology has been under development for more than a decade
and is known for pioneering the production of a bovine protein in a crop for the food industry. Moolec&rsquo;s product portfolio and pipeline
leverages the agronomic efficiency of broadly used target crops, like soybean, pea, and safflower to produce oils and proteins. The Company
has an industrial and commercial R&amp;D capability to complement their Molecular Farming technology and secures a growing international
patent portfolio (25+, both granted and pending) for its technology. Moolec is run by a diverse team of Ph.Ds and Food Insiders, and operates
in the United States, Europe, and South America. For more information, visit moolecscience.com and ir.moolecscience.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains
&ldquo;forward-looking statements.&rdquo; Forward-looking statements may be identified by the use of words such as
&ldquo;forecast,&rdquo; &ldquo;intend,&rdquo; &ldquo;seek,&rdquo; &ldquo;target,&rdquo; &ldquo;anticipate,&rdquo;
&ldquo;believe,&rdquo; &ldquo;expect,&rdquo; &ldquo;estimate,&rdquo; &ldquo;plan,&rdquo; &ldquo;outlook,&rdquo; and
&ldquo;project&rdquo; and other similar expressions that predict or indicate future events or trends or that are not statements of
historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the
business of Moolec are predictions, projections and other statements about future events that are based on current expectations and
assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each
forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts
and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will
prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause
actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the
possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the
scaling up of Moolec&rsquo;s business and other risks and uncertainties, including those included under the header &ldquo;Risk
Factors&rdquo; in Moolec&rsquo;s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission
(&ldquo;SEC&rdquo;), as well as Moolec&rsquo;s other filings with the SEC. Should one or more of these risks or uncertainties
materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in
these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result
of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should
not put undue reliance on these statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Moolec Science&rsquo;s Contacts:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Press &amp; Media inquiries: comms@moolecscience.com</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Investor Relations inquiries: ir@moolecscience.com | MoolecIR@icrinc.com</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !: (<# 2(  A$! Q$!_\0
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M([Z?=7L&V9@#Z[HKY-_;!_;<_9B_83^$^H_&3]J+XN>'/A1X.LVDBTX:M/\
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MOA'X;M-=D:"Q.H_$&>V.B^*(;:^,VCVV@^+=C--9Q";R_P#X+Y_\$XO#S_\
M!:;PC^QA_P $_OV>_#_A/5_B[\+/A++X8^%7PWTRWT'PV?%6K:=J\NMZZUL[
MQ:?H6G0Z=I3ZKXDU.>2WLK2TLKO4KLADE+@'\VGQ1^-WQE^-^O+XI^,OQ6^(
MOQ6\21IY<>N_$7QGXA\9:M%'Q\D-]XAU#4+B%. 2L<B GD@FO,"222222222
M<DD\DDGDDGJ:_JV\3?\ !IM^U%;^'O%OAWX;?MB?L<?%_P#:F^'_ (>;Q%XU
M_9.\'^.;M/B+ID4=M]JDTRTO+Q 9-6D7$5DFMZ)X=TZZG:.-M2@$D;-^3?\
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M3_$'C+2O!^AZ+<A -MW<Z%XAA#<&SE5B5_M8_8#_ ."6/[%O_!-_X=VW@?\
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MM+T/1-'TR%;>PTO2=,LHX;.QL;*!5@MX+>&-$B1%Q\HKH:** "BBB@ HHHH
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M@_Q5X3\6>!4\;>,I;WPP_AGP]>+H>F^*+>SM?';Z;JNBZQIWVZ"UMM0@MI"
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M_P ([+4--^%_AB6'6+NYW>$O FG:I>:=X?T64RBVL3:VDEQ+!I]@EOU.A?\
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:)M0NKVZ=YS],44 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
